Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Ingiboyon Jan 30, 2023 1:31pm
85 Views
Post# 35254366

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:market CRAZYNESS

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:market CRAZYNESS
Genie29j wrote:

Nope - but I'm also not screaming "greed". 

What I am saying it's if people are claiming the Replicel team is "greedy" because they are buying at these low prices - it's a false claim bc WE ALL have  access to these special share offerings and/or the open market.

The way I see it is They (the Replicel team - aka Andrew) are doing everything they can keep this company afloat - I think every shareholder should be grateful for their investments vs criticizing. They clearly feel good about things, but need cash to at minimum get through the Shiseido hearing and getting the device to market. I cannot image they are pumping more cash into this company if they weren't optimistic. They may see the pot of gold at the end of this dark forest 

tgat said, I may invest on this round. I am already (very) heavily overweight in this company - so I am unsure I want to risk even more at this point, but tbd - I have bought more open market shares this past week. I would ideally like to see some positive news being released before I risk even more. 



Remember Genie29j:  "Greed is good". haha

Seriously though I am on your side here regarding infusing working capital into a cash strapped company through PP's.  This is a pivotal year for Replicel and they need working capital to ride out the year to get the Arbitraitor's judgement mid year and the Dermal Injector to market.  That is a given for all of us. No one disputes that.  
The downside is these PP's stifle retail buying.  The current average volume is approx. 9,500 which is not enough to move the share price.  This past few years have been one PP after another.  Why would anyone buy on the open market when as you say they can buy into these cheap PP's at $.10.  
Enough is enough !  Let's now see some volume in the exchanges where Replicel is traded.  If anyone wanting in now were to buy retail we might see some upward movement.  Also in the last PP announcement there was not a closing date which is a bit odd. 

<< Previous
Bullboard Posts
Next >>